DOCSLIB.ORG

List of Manufacturers and Distributors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Manufacturers and Distributors THE IMMUNOASSA Y KIT DIRECTORY, SERIES B, VOLUME 1, PART 3 (ENTERIC AND OTHER INFECTIONS) 987 LIST OF MANUFACTURERS AND DISTRIBUTORS Germany Fax: + 64-9-2746633 Norden Road Abbott Tel: +49-61-2250101 Maidenhead Laboratories Fax: + 49-61-22501244 PHILIPPINES Berkshire, SL6 4XF Telex: 4182598 Abbott Laboratories (Phils) United Kingdom Corporate Inc Tel: +44-01628-784041 Abbott Laboratories GREECE POB 29 Fax: + 44-01628-644205 Diagnostics Division Abbott Laboratories (Hellas) Commercial Center Abbott Park SA Makati USA North Chicago, IL 60064 Diagnostics Division Metro Manila Abbott Laboratories USA 194 Syngrou Ave Philippines Diagnostics Division Tel: + 1-312-937-6100 Athens Tel: + 63-2-6318471 1921 Hurd Greece Fax: + 63-2-6318488 PO Box 152020 By region Tel: + 30-1-9519019 Irving, TX 75015-2020 AUSTRALIA Fax: + 30-1-9592790 PORTUGAL USA Abbott Australasia Pty Ltd ABBOTT Laboratorios Ltd Tel: + 1-214-518-6000 Diagnostics Division HONG KONG Apartado 20/Alfragide PO Box 394 Abbott Laboratories Ltd 2700 Amadora Abbott Laboratories North Ryde, NSW 2113 Unit No. 3005, 30/F Portugal Diagnostics Division Australia West Tower, Shun Tak Centre Tel: + 351-1-4712575 Abbott Park Tel: +61-2-8881111 200 Connaught Road Fax: +351-1-4712725 North Chicago, IL 60064 Hong Kong Fax: + 61-2-8873948 USA Tel: 852-5490019 + PUERTO RICO Tel: + 1-312-937-6100 AUSTRIA Fax: + 852-8580498 Abbott Laboratories Diagnostics Division Abbott GmbH Abbott Laboratories IRELAND PO Box 4706 Diagnostics Division Diagnostics Division Abbott Laboratories Ireland Carolina 00628 Diefenbachgasse 35 820 Mission St Ltd Puerto Rico 1150 Vienna South Pasadena, CA 91030 70 Broomhill Road Tel: 1-809-7623366 Austria + USA Tel: +43-1-89124 Tallaght, Dublin 24 Fax: + 1-809-7505454 Ireland Tel: + 1-818-440-0700 Fax: +43-1-8941747 Tel: + 353-16-517388 SINGAPORE Fax: 353-16-517765 BELGIUM + Abbott Laboratories Private Abbott SA Ltd I Alexon ITALY GPO Box 1016 Diagnostics Division Abbott SpA Singapore 9020 Rue du Bosquet 2 Corporate Divisione Diagnostici Singapore 1348 Ottognies- Alexon Via Mar della Ciria 262 Louvain-Ia-Neuve Tel: + 65-2788343 1190 Borregas Avenue 00144 Rome Belgium Fax: + 65-2708873 Sunnyvale, CA 94089-1302 Italy Tel: +32-10-475311 USA Tel: + 39-6-529911 SOUTH AFRICA Fax: + 32-10-475334 Tel: + 1-408-747-7000 Fax: + 39-6-52991436 Abbott LABS South Africa Fax: + 1-408-747-7011 (pty) Ltd CANADA JAPAN Diagnostics Division Abbott Laboratories Ltd Dainabot Co Ltd PO Box 1616 Diagnostics Division 33 Mori Building 6th floor Johannesburg 2000 I Alfa Biotech 7115 Milcreek Drive 8-21 Toranomon 3-chome South Africa Mississauga Minato-ku Tel: +27-11-4941957 Corporate Ontario, L5N 3R3 Tokyo 105 Fax: + 27-11-4943041 Alfa Biotech Canada Japan Viale Sarca 223 Tel: 1-416-858-2450 + Tel: + 81-3-34379441 SPAIN 20126 Milan Fax: 1-416-858-2462 + Fax: + 81-3-34379367 Abbott Cientifica SA Italy Costa Brava, 13 Tel: +39-2-661381 DENMARK MEXICO 28034 Madrid Fax: + 39-2-66138443 Abbott A/S Abbott Laboratories de Spain Diagnostics Division Mexico SA Tel: + 34-1-3373400 Bygstubben 16 Diagnostics Division Fax: + 34-1-7349664 Troeroed Amico Laboratories Apartado Postal No 44-983 Inc 2950 Vedbaek Mexico 03100, D.F. SWEDEN Denmark Mexico Abbott AB Corporate Tel: + 45-42-894452 Tel: +52-5-7264600 Diagnostics Division Amico Laboratories Inc Fax: +45-42-890132 Fax: + 52-5-7264644 PO Box 1074 PO Box 90203 16421 Kista-Stockholm 5012 Illinois Avenue FRANCE NETHERLANDS Sweden Nashville, TN 37209 Laboratoires Abbott Abbott NV Tel: 46-8-7036700 + USA Division Diagnostic Maalderij 21 Fax: +46-8-7527123 12 rue de la Couture 1185 ZB Amstelveen Tel: + 1-615-385-3114 Fax: 1-615-385-3114 Silic 203 Netherlands SWITZERLAND + 94518 Rungis Cedex Tel: + 31-20-5454540 Abbott AG France Fax: +31-20-6402231 Diagnostics Division Tel: + 33-1-45602500 Gewerbestrasee 5 I AMRAD Biotech Fax: + 33-1-45600498 NEW ZEALAND 6330 Cham/Zug Abbott Laboratories (NZ) Ltd Switzerland Corporate GERMANY Diagnostics Division Tel: +41-42-444400 AMRAD Biotech Abbott Diagnostic Products 146 Harris Road Fax: +41-42-415140 34 Wad hurst Drive GmbH PO Box 58-611 Boronia, Victoria 3155 Max-Planck-Ring 2 Greenmount, Auckland UNITED KINGDOM Australia 65205 Wiesbaden- New Zealand Abbott Diagnostics Tel: +61-3-9887-3909 Delkenheim Tel: + 64-9-2749886 Abbott House Fax: + 61-3-9887-3007 © KLUWER ACADEMIC PUBLISHERS 1995, ISSN 1381-5067 988 THE IMMUNOASSAY KIT DIRECTORY, SERIES S, VOLUME 1, PART 3 (ENTERIC AND OTHER INFECTIONS) By region By region 11 rue Aristide Berges Dubai AUSTRALIA USA 38800 Pont de Claix United Arab Emirates AMRAD Biotech Bard Diagnostic Sciences Inc France Tel: +971-4-379525 34 Wadhurst Drive 12277 134th CT NE Tel: +33-76683636 Fax: +971-4-379551 Boronia, Victoria 3155 Redmond, WA 98052 Fax: + 33-76683604 Australia USA UNITED KINGDOM Tel: + 61-3-9887-3909 Tel: + 1-206-814-1604 Becton Dickinson Europe Becton Dickinson UK Ltd Fax: +61-3-9887-3007 Fax: + 1-206-814-1607 Diagnostics Division Between Towns Road 5 chemin des Sources Cowley Trace Scientific Seradyn Inc BP 37 Oxford, OX4 3LY 1860 Princes Highway PO Box 1210 38240 Meylan Cedex United Kingdom Clayton, Victoria 3168 Indianapolis, IN 46206 France Tel: +44-01865-748844 Australia USA Tel: +33-76416464 Fax: +44-01865-787313 Tel: +61-3-9543-1255 Tel: + 1-317-266-2000 Fax: +33-76418560 Fax: +61-3-9543-6719 Fax: + 1-317-266-2991 USA GERMANY Beclon Dickinson JAPAN Becton Dickinson GmBH Immunodiagnostics Sumitomo Metal Industries Becton Dickinson Postfach 10 16 29 Mountain View Avenue Ltd Immuno- 69006 Heidelberg Orangeburg, NY 10962-1294 16-1 Sunayama Germany USA Hasaki-Cho Kashima-Gun diagnostics Tel: + 49-6221-3050 Tel: + 1-914-359-2700 Ibaraki 314-02 Fax: +49-6221-305216 Fax: + 1-415-966-8914 Japan Corporate Tel: + 81-479-465136 Becton Dickinson GREECE Fax: + 71-479-465146 Immunodiagnostics Becton Dickinson Hellas SA Mountain View Avenue 36A lonias Street I Behringwerke AG MALAYSIA Orangeburg, NY 10962-1294 17456 Alimos Kyowa Hakko (Kalupa) USA Athens 138 Corporate 20 Jalan SS 19/5 Tel: + 1-914-359-2700 Greece Behringwerke AG 47500 Subang Jaya Fax: + 1-415-966-8914 Tel: + 30-1-9941558 Postfach 1140 Selangor Darul Ehsan Fax: + 30-1-9941672 35001 Marburg Malaysia By region Germany Tel: + 60-3-7340669 AUSTRIA ITALY Tel: +49-6421-390 Fax: + 60-3-7340990 Laevosan GmbH Becton Dickinson Italia SpA Fax: +49-6421-66064 Estermannstrasse 17 Via Caldera 21 Telex: 48232001 SINGAPORE 4020 Linz 20153 Milan Kyowa Hakko Industry (S) Pte Austria Italy By region Ltd Tel: +43-732-7651 Tel: + 39-2-482401 ANTILLES 300 Orchard Road #06-02 Fax: + 43-732-782833 Fax: + 39-2-48203520 Curacao Pharmacal Company The Promenade NV Singapore 0923 BELGIUM NETHERLANDS Ontarioweg 8 Singapore Becton Dickinson Benelux NV Becton Dickinson BV Salinja Curacao, NA Tel: +65-7334948 Denderstraat 24 Mon Plaisir 89B PO Box 252 Fax: +65-7330819 POB13 Postbus 514 Willemstad, Curacao 9320 Erembodegem-Aalst 4870 AM Etten-Leur Antilles TAIWAN Belgium Netherlands Fax: + 599-9-614819 Target Science Inc Tel: + 32-53-720211 Tel: + 31-1608-37720 Telex: 1256 2F No. 142-1, Sec 1 Fax: + 32-53-720200 Fax: +31-1608-14133 Shing Shang S Rd ARGENTINA Taipei Beckton Dickinson SPAIN Merck Quimica Argentina Taiwan Middle East and African Becton Dickinson SA SAIC Tel: +886-2-3417866 Operations Camino de Valdeoliva sIn Behring Diagnosticos Fax: +886-2-3416192 Denderstrat 24 San Agustin de Guadalix Artilleros 2436 Postbus 13 28750 Madrid 1428 Buenos Aires 9320 Erembodegem Spain Argentina Belgium Tel: + 34-1-8418311 IArgene-Biosoft Tel: +54-1-7886558 Tel: 32-61-3225717 + Fax: +34-1-8418113 Fax: + 54-1-7883365 Corporate Fax: + 32-61-3225830 Argene-Biosoft SWEDEN AUSTRALIA EASTERN EUROPE Becton Dickinson AB Parc Technologique Behring DiagnostiCS Australia Becton Dickinson GmbH Box 32045 Delta Sud BP 24 Ply Ltd Postfach 10 16 29 126 11 Hagersten Varilhes 09120 103 Vanessa SI. Kingsgrove 69006 Heidelberg Sweden France 2208 Germany Tel: +46-8-180030 Tel: +33-61696100 Locked Mail Bag 200 Tel: +49-6221-3050 Fax: + 46-8-6450808 Fax: +33-61696101 Kingsgrove, NSW 2208 Fax: + 49-6221-305254 Australia SWITZERLAND Tel: +61-2-5541600 FINLAND Becton Dickinson AG 61-2-5024256 Bard Diagnostic Becton Dickinson OY PO Box Fax: + Sciences Inc Takomotie 8A 4002 Basel 00380 Helsinki Switzerland AUSTRIA Corporate Finland Tel: +41-61-3225717 Behring Institut GmbH Bard Diagnostic Sciences Inc Tel: + 358-90-50621 00 Fax: +41-61-3225830 Altmannsdorfer Str 104 12277 134th CT NE Fax: + 358-90-5062088 1127 Vienna Redmond, WA 98052 UNITED ARAB EMIRATES Austria USA FRANCE Becton Dickinson Diagnostics Tel: +43-1-80101 Tel: + 1-206-814-1604 Becton Dickinson France SA Division Telex: 133701 Fax: + 1-206-814-1607 Division Diagnostic PO Box 52279 © KLUWER ACADEMIC PUBLISHERS 1995, ISSN 1381-5067 THE IMMUNOASSAY KIT DIRECTORY, SERIES B, VOLUME 1, PART 3 (ENTERIC AND OTHER INFECTIONS) 989 BAHAMAS CANADA Tel: + 593-2-562703 GUATEMALA Lowe's Pharmacy Ltd Hoechst Roussel Canada Inc Fax: + 593-2-651150 Quimica Hoechst de PO Box N-7504 4045 Cote Vertu Telex: 2252 Guatemala SA Nassau Montreal Diagnosticos Behring Bahamas Quebec H4R ZE8 EGYPT Apartado 155 Tel: + 1-809-3228006 Canada Hoechst Orient SAA km 15.5 Carretera Roosevelt Telex: 20477 Tel: + 1-514-333-3605 PO Box 1486 Guatemala City Fax: + 1-514-333-3769 3 Sharia EI Massaneh Guatemala BAHRAIN (Zeitoun) Tel: + 502-2-91 0011/15 Bahrain Pharmacy & General CHILE Cairo Fax: + 502-2-954016 Store Merck Quimica Chilens Ltd Egypt Telex: 5946 PO Box 403 Casilla 4232 Tel: + 20-2-2575840 Bahrain Santiago de Chile Fax: + 20-2-694 755 GUYANA Tel: +973-53491/255506 Chile Telex: 02331 Guyana Pharmaceutical Corp Fax: +973-275195 Tel: + 56-2-2381160 Ltd Telex: 8979 Fax: + 56-2-2383527 EL SALVADOR PO Box 160 Telex: 440197 La Penitence, Demerara Quimica Hoechst de EI BANGLADESH Salvador SA Guyana Tel: +592-632815 Hoechst Bangladesh Co.
Load more

Recommended publications
  • Energy Efficiency And
    Progress with The Energy Policy Review: A Perspective OIES Seminars 7 October 2003 John Bower Overview What the White Paper Said Reality Dawns An alternative 20:20 Vision John Bower Progress on UK Energy White Paper 2 What the White Paper Said UKEWP refocused energy policy away from a UK driven liberalisation agenda… GOALS AND POLICIES 1. Reduce CO2 emissions by 60% by 2050 Reduce amount of energy we consume Central to future market and policy will be emissions trading Raise efficiency standards in home appliances and housing Encourage low carbon fuels and renewables through grants and subsidy 2. Maintain reliability of energy supplies Right infrastructure / regulatory systems in UK and liberalisation of Europe Pursue regional stability and economic reform in producing areas Promote understanding of markets and conditions for FDI in producing areas Forward prices will signal the need for investment Improve contingency planning in dealing with major incidents John Bower Progress on UK Energy White Paper 3 What the White Paper Said …. towards an EU driven multifaceted agenda GOALS AND POLICIES 3. Promote competitive markets in UK and beyond Raise rate of sustainable economic growth Support business and competitiveness through reliable / affordable energy Encourage firms to innovate, reduce cost, deliver better goods and services Use market based instruments to deliver policy goals Work with business to prepare them for the low carbon economy of the future 4. Ensure that every home is adequately and affordably heated Reduce poverty by lowering prices and raising social security payments Improve quality of housing stock via insulation and energy efficiency grants John Bower Progress on UK Energy White Paper 4 What the White Paper Said UKEWP relied on carbon trading and uneconomic/unproven technology… ENERGY SYSTEM IN 2020 1.
    [Show full text]
  • MI4A Vaccine Purchase Data for Countries This Note Is Intended to Guide Countries in Their Use of the MI4A Vaccine Purchase Data
    MI4A Vaccine Purchase Data for Countries This note is intended to guide countries in their use of the MI4A vaccine purchase data. What data is available? new vaccine introductions, but also for product switches – and to understand the status of product The WHO vaccine market intelligence database registrations. Fifty-six Member States responded compiles vaccine purchase (product, price and to these new questions. procurement) data as reported by countries via the WHO/UNICEF Joint Reporting Form (JRF) over the This information is essential to WHO’s efforts to period of 2013–2018. While country names are not improve global market forecasts and inform displayed, data is publicly available on the MI4A suppliers’ and global policy-makers’ investment website and provides information by country decisions. WHO encourages all countries to characteristics (e.g. region, income group…) by report information on new introduction plans and vaccine and by year of purchase, along with price planned product changes as well as to respond to per dose (USD), procurement mechanism and questions related to registration. annual volumes. 1 The number of countries reporting vaccine How can my country use this data? purchase data through the JRF continues to Countries can use the vaccine purchase data in increase year after year, with 182 Member States several different ways, such as to: (93%) reporting some vaccine procurement information in 2019 – including 158 (81%) fully • Understand how the price of vaccines in their reporting on vaccine purchase data. Price reporting immunization schedule relate to other this year marks a 3% increase from last year and products on the market, or compare the more than triple the reporting from 2016.
    [Show full text]
  • Contribution of Podoviridae and Myoviridae Bacteriophages
    www.nature.com/scientificreports OPEN Contribution of Podoviridae and Myoviridae bacteriophages to the efectiveness of anti‑staphylococcal therapeutic cocktails Maria Kornienko1*, Nikita Kuptsov1, Roman Gorodnichev1, Dmitry Bespiatykh1, Andrei Guliaev1, Maria Letarova2, Eugene Kulikov2, Vladimir Veselovsky1, Maya Malakhova1, Andrey Letarov2, Elena Ilina1 & Egor Shitikov1 Bacteriophage therapy is considered one of the most promising therapeutic approaches against multi‑drug resistant bacterial infections. Infections caused by Staphylococcus aureus are very efciently controlled with therapeutic bacteriophage cocktails, containing a number of individual phages infecting a majority of known pathogenic S. aureus strains. We assessed the contribution of individual bacteriophages comprising a therapeutic bacteriophage cocktail against S. aureus in order to optimize its composition. Two lytic bacteriophages vB_SauM‑515A1 (Myoviridae) and vB_SauP‑ 436A (Podoviridae) were isolated from the commercial therapeutic cocktail produced by Microgen (Russia). Host ranges of the phages were established on the panel of 75 S. aureus strains. Phage vB_ SauM‑515A1 lysed 85.3% and vB_SauP‑436A lysed 68.0% of the strains, however, vB_SauP‑436A was active against four strains resistant to vB_SauM‑515A1, as well as to the therapeutic cocktail per se. Suboptimal results of the therapeutic cocktail application were due to extremely low vB_SauP‑436A1 content in this composition. Optimization of the phage titers led to an increase in overall cocktail efciency. Thus, one of the efective ways to optimize the phage cocktails design was demonstrated and realized by using bacteriophages of diferent families and lytic spectra. Te wide spread of multidrug-resistant (MDR) bacterial pathogens is recognized by the World Health Organi- zation (WHO) as a global threat to modern healthcare1.
    [Show full text]
  • List of Registred Drugs in Armenia (01.03.2017-31.03.2017)
    LIST OF REGISTRED DRUGS IN ARMENIA (01.03.2017-31.03.2017) International nonproprietary name Dose and Registration Term of Legal Status N Trade name Drug form Manufacturer Country ATC1 code License holder (generic) or active packaging number registration for Supply ingredients name Eli Lilly Regional Lilly France S.A.S., Operations GmbH., solution for 100IU/ml, Zone Industrielle, 2 17.03.2017 1 Abasaglar insulin glargine France A10AE04 16535 PoM2 Koelblgasse 8-10, injection 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 1030, Vienna, 67640 Fegersheim Austria Olainfarm JSC, 5 300mg, Olainfarm JSC, 5 06.03.2017 Rupnicu Str., 2 Adaptol mebicar capsules hard in blister (20/2x10/, Rupnicu Str., Olaine, Latvia N06BX21 16440 PoM 06.03.2022 Olaine, LV-2114, 30/3x10/, 40/4x10/) LV-2114 Latvia Olainfarm JSC, 5 Olainfarm JSC, 5 500mg, 06.03.2017 Rupnicu Str., 3 Adaptol mebicar tablets Rupnicu Str., Olaine, Latvia N06BX21 16441 PoM in blister (20/2x10/) 06.03.2022 Olaine, LV-2114, LV-2114 Latvia 10mg, Pharmstandard- OTCPharm PJSC, fabomotizole in blisters Leksredstva JSC, 27.03.2017 123317, Moscow, 4 Afobazol (fabomotizole tablets (30/1x30/, 60/3x20/, 305022, Kursk, Russia N05BX04 14729/2 PoM 30.07.2020 Testovskaya str., 10, dihydrochloride) 60/2x30/, 90/3x30/, Agregatnaya 2nd str., Russia 120/4x30/) 1a/18 Gedeon Richter 15mg/g, Gedeon Richter PLC, 17.03.2017 PLC, Gyomroi ut 5 Airtal aceclofenac cream 60g aluminium Gyomroi ut 19-21, Hungary M01AB16 16514 OTC3 17.03.2022 19-21, 1103 tube 1103 Budapest Budapest, Hungary 1 Gedeon Richter PLC, Gyomroi ut 19-21, 1103 Budapest - batch releaser, Industrias Gedeon Richter Farmaceuticas powder for oral 100mg, 17.03.2017 PLC, Gyomroi ut 6 Airtal aceclofenac Almirall S.L., Ctra.
    [Show full text]
  • Annex 2 Composition of Oral and Injectable Estrogen–Progestogen Contraceptives
    ANNEX 2 COMPOSITION OF ORAL AND INJECTABLE ESTROGEN–PROGESTOGEN CONTRACEPTIVES Annex 2 lists the composition of brands of estrogen–progestogen preparations used in combined injectables (Table 1), combined oral (Table 2) and phasic oral (Table 3) contraceptives. The countries in which these formulations are used are noted. Are listed only those brands for which availability was reported. The source of these tables is the International Planned Parenthood Foundation (IPPF). Data have been taken from the IPPF 2002 website [http://contraceptive.ippf.org] at the time of the monograph meeting (June 2005). This online site is regularly updated. Table 1. Combined injectables Brand name Composition Countries of availability Acefil Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Agurin Dihydroxyprogesterone acetophenide 150 mg Chile + estradiol enanthate 10 mg Anafertin Dihydroxyprogesterone acetophenide 75 mg El Salvador, Mexico + estradiol enanthate 5 mg Ciclofem Medroxyprogesterone acetate 25 mg Guatemala + estradiol cypionate 5 mg Ciclofemina Medroxyprogesterone acetate 25 mg El Salvador + estradiol cypionate 5 mg Ciclomes Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Ciclovular Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Clinomin Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Cyclofem Medroxyprogesterone acetate 25 mg Chile, Indonesia, Malaysia, Mexico, + estradiol cypionate 5 mg Panama, Zimbabwe Cyclofemina Medroxyprogesterone
    [Show full text]
  • Vaccine Purchase Data and Cover Note for Countries
    MI4A Vaccine Purchase Data for Countries The MI4A Vaccine Purchase How can my country use this data?1 Database What data is available? • • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 1 Immunization Agenda IA 2030 Reporting Vaccine Purchase Data Documenting use of MI4A data WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 2 Key messages to countries • • • 7 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 3 • • • • • . / WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 4 • • • • • • • 12 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 5 • • • • • • • • 13 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 6 • • • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 7 What is MI4A? • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 8 A. Available Products List - as known to WHO The MI4A Products List provides a snapshot overview of vaccine products available for procurement – irrespective of their WHO prequalification status – as of November 2020. This list reflects information reported by countries through the 2020 Joint Reporting Form (JRF) and is supplemented with available information gathered through separate consultations. As part of the MI4A project, WHO conducts in-depth global market studies where the list of available vaccines can be considered comprehensive and up to date. Studies conducted so far include BCG, D&T-containing, measles-containing, meningococcal, HPV, pneumococcal, rabies, and typhoid vaccines. For all the other vaccines it should be noted that this list may not be complete and may be missing some products whose availability is not documented through public reported data and sources.
    [Show full text]
  • Biotechnology in Russia: Why Is It Not a Success Story?
    Biotechnology in Russia: Why is it not a success story? Biotechnology inRussia:Whyisitnotasuccessstory? ROGER ROFFEY Biotechnology in Russia: Why is it not a success story? According to President Medvedev 2009 ‘By and large, our industry continues to make the same outdated products and, as a rule, imported generics from substances bought abroad. There is practically no work to create original medicines and technologies.’…‘We must begin the modernisation and technological upgrading of our entire industrial sector. I see this as a question of our country’s survival in the modern world’… ‘These are the key tasks for placing Russia on a new technological level and making it a global leader’. Many states including Russia see biotechnology and its commercialization as a key driver for their future growth. The biotechnology area is characterized by being a very knowledge-intensive activity where there is increasing global competition for know-how. Russia had a very good historical base of R&D and know- how in biotechnology from the previous Soviet military programme. There have been many attempts since 2000 to revive the Russian biotechnology industry not least in 2005 but without much success. In 2009 there were again very ambitious programmes and strategies developed as well as techno-parks for the ROGERROFFEY development of the biotechnology and pharmaceuticals industry up to 2020. It has also been announced by President Medvedev the creation of a Russian equivalent to ‘Silicon Valley’ to include R&D also in biotechnology outside Moscow. There have been many such grand plans but so far they have not been very successful and the question for this study was if it would be different this time? Why are scientists still leaving Russia and foreign investors still hesitating to invest in Russian biotechnology or pharmaceuticals? Why is Russia still not able to compete on the global biotechnology market and is ranked only as number 70 in the world? The current problems and prospects for the biotechnology and pharmaceuticals industries are analysed.
    [Show full text]
  • PR-Bird Flu-CCX-[MASTER]
    Avian Flu D-125TM H5N1 It's not a matter of if... it's a matter of WHEN BELIEVED BY US EPA TO KILL AVIAN FLU D-125 is a US EPA-registered sanitizer, disinfectant and cleaner effective against several strains of the Avian Flu. The US EPA does not currently have any products that are regis- tered against the particular H5N1 strain of Avian Flu; however, the US EPA has indicated that they believe D-125 will prove effective against H5N1 once testing is completed. These products are available in an economical concentrate and ready-to-use spray and wipe formulation. Both the concentrate and the ready-to-use are US EPA-registered to kill an extraor- dinary range of 120 plus microbial organisms including all of the pan-demic human influenza strains of the 20th century including: Influenza A / Brazil Virus Influenza A / Victoria (H3N2) Virus Influenza A2-Asian Virus Influenza B Virus (Allen Strain) Influenza C Virus (Taylor Strain) D-125 is a registered tademark of Microgen Inc. Parainfluenza Type 1 In addition to being among a select group of products believed effective against H5N1 Avian Flu Virus, D-125 registered for use in and has specific instructions for disinfecting poultry houses as well as meat, poultry and food processing plants. Microgen Inc. D-125 is also registered for use on both hard, non-porous Clinton Square Executive Center surfaces and on porous surfaces. West Caldwell, NJ 07006 USA www.microgeninc.com With such versatility and efficacy D-125 is the ultimate choice 1-800-420-7522 or 973-575-9025 when disinfecting and sanitizing.
    [Show full text]
  • Live Attenuated Influenza Vaccines Against
    ccines & a V f V a o c l c i a n n a Larionova et al., J Vaccines Vaccin 2013, 4:8 r t u i o o n DOI: 10.4172/2157-7560.1000208 J Journal of Vaccines & Vaccination ISSN: 2157-7560 Research Article Open Access Live Attenuated Influenza Vaccines against Highly Pathogenic H5N1avian Influenza: Development and Preclinical Characterization Natalie Larionova1*, Irina Kiseleva1, Irina Isakova-Sivak1, Andrey Rekstin1, Irina Dubrovina1, Ekaterina Bazhenova1, Ted M Ross2, David Swayne3, Larisa Gubareva4, Vadim Tsvetnitsky5, Ekaterina Fedorova1, Elena Doroshenko1 and Larisa Rudenko1 1Institute of Experimental Medicine, St. Petersburg, Russia 2University of Pittsburgh, Pittsburgh, PA, USA 3Southeast Poultry Research Laboratory, Athens, GA, USA 4Centers for Disease Control and Prevention, Atlanta, GA, USA 5PATH (Program for Appropriate Technologies in Health), USA Abstract In this paper we describe the development and the outcomes of the preclinical studies of temperature-sensitive and cold-adapted candidates for live attenuated influenza vaccine (LAIV) based on highly pathogenic avian influenza viruses A/H5N1 with pandemic potential. The LAIV candidates were developed by methods of classical re- assortment between H2N2 Master Donor Virus for Russian LAIV and H5N1 viruses generated by reverse genetics for inactivated vaccine. These reverse genetically generated viruses were chosen as a source of H5 hemagglutinin and contained a modified protease cleavage site believed to be associated with high virulence. The progeny of re- assortment had 7:1 gene composition and were characterized by antigen specificity of the HA of the pandemic virus, a high growth rate in chicken embryos and their parameters of temperature sensitivity and cold adaptation confirmed preserved attenuation of the Master Donor Virus.
    [Show full text]
  • Dagestan Blunt-Nosed Viper, Macrovipera Lebetina Obtusa (Dwigubsky, 1832), Venom
    Toxicon:X 6 (2020) 100035 Contents lists available at ScienceDirect Toxicon: X journal homepage: www.journals.elsevier.com/toxicon-x Dagestan blunt-nosed viper, Macrovipera lebetina obtusa (Dwigubsky, 1832), venom. Venomics, antivenomics, and neutralization assays of the lethal and toxic venom activities by anti-Macrovipera lebetina turanica and anti-Vipera berus berus antivenoms Davinia Pla a, Sarai Quesada-Bernat a, Yania Rodríguez a, Andr�es Sanchez� b, Mariangela� Vargas b, b b � b c d Mauren Villalta , Susana Mes�en , Alvaro Segura , Denis O. Mustafin , Yulia A. Fomina , Ruslan I. Al-Shekhadat d,**, Juan J. Calvete a,* a Laboratorio de Venomica� Evolutiva y Traslacional, CSIC, Jaime Roig 11, 46010, Valencia, Spain b Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San Jos�e, 11501-206, Costa Rica c LLC Olimpic Medical, Tashkent, Uzbekistan d LLC Innova Plus, Saint-Petersburg, 198099, Russia ABSTRACT We have applied a combination of venomics, in vivo neutralization assays, and in vitro third-generation antivenomics analysis to assess the preclinical efficacyof the monospecific anti-Macrovipera lebetina turanica (anti-Mlt) antivenom manufactured by Uzbiopharm® (Uzbekistan) and the monospecific anti-Vipera berus berus antivenom from Microgen® (Russia) against the venom of Dagestan blunt-nosed viper, Macrovipera lebetina obtusa (Mlo). Despite their low content of homologous (anti-Mlt, 5–10%) or para-specific (anti-Vbb, 4–9%) F(ab’)2 antibody fragments against M. l. obtusa venom toxins, both antivenoms efficiently recognized most components of the complex venom proteome’s arsenal, which is made up of toxins derived from 11 different gene families and neutralized, albeit at different doses, key toxic effects of M.
    [Show full text]
  • Nanolek - R U S S I a N Pharmacuetical Company - Overview
    NANOLEK - R U S S I A N PHARMACUETICAL COMPANY - OVERVIEW November, 2014 SUMMARY NANOLEK aimed to become one of the leading Russian pharmaceutical companies by 2018 NANOLEK is a biopharmaceutical company that sets up a state-of-the-art manufacturing facilities with portfolio focus on prescription drugs for high disease burden and priority therapeutic areas: vaccines, oncology, rheumatology, orphan drugs, antiretroviral products Portfolio structure Manufacturing facility Sales pattern, 2018, forecast 2014 . Full compliance with best industry practice in respect to labour and environmental standards . Full EU GMP compliance Well-balanced portfolio: • Vaccines; • Biosimilars; • Orphan drugs; • ARV and others; Ownership structure The company is 51% owned by Russian private shareholders and 49% - by state investment fund JSC Rusnano. 2 CONTENT Russian market overview Portfolio Strategy Manufacturing Sales & Distribution Team Value proposition 3 In 2014 Russian pharmaceutical market is about to reach USD18 bln. level. M A R K E T Key market drivers: new categories expansion, OVERVIEW demand for modern treatment, governmental programs. USD Bln. Insurance 6% Medicines DLO/7N 28.0 insurance (2018) 6.6 Hospital segment 22.2 3,0 Retail 10% 2,7 5,0 7N 4.8 introduction 4,8 13.0 18,0 DLO introduction 3,3 14,7 4.0 1.7 0,8 7,7 0,3 1.3 2,3 2000 2005 DLO 2010 DLO/7N 2016 2020 4 MARKET TRENDS: LOCALIZATION AND R&D Government wants to grow local … as well as increase the share manufacturers … of innovative drugs 100% = 100 100 100% = 100 100 Branded 50 generics
    [Show full text]
  • Turnover of Soil Microbial Diversity Is Driven by Wide-Scale Environmental Heterogeneity Nicolas Chemidlin Prévost-Bouré, Samuel Dequiedt, Lionel Ranjard
    Turnover of soil microbial diversity is driven by wide-scale environmental heterogeneity Nicolas Chemidlin Prévost-Bouré, Samuel Dequiedt, Lionel Ranjard To cite this version: Nicolas Chemidlin Prévost-Bouré, Samuel Dequiedt, Lionel Ranjard. Turnover of soil microbial di- versity is driven by wide-scale environmental heterogeneity. 2. Thünen Symposium on Soil Metage- nomics, Conventus Congressmanagement & Marketing GmbH. Jena, DEU., Dec 2013, Braunschweig, Germany. pp.39. hal-01004768 HAL Id: hal-01004768 https://hal.archives-ouvertes.fr/hal-01004768 Submitted on 3 Jun 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 2nd Thünen SympoSium on Soil meTagenomicS Mining and learning froM MetagenoMes plus Workshop on Bioinformatic tools december 11–13, 2013 Braunschweig, germany AMME R OG R www.soil-metagenomics.org p Scientific programme overview Wednesday, 11 December 2013 Thursday, 12 December 2013 Friday, 13 December 2013 08:00 08:30–10:00 Workshop on bioinformatic tools: 09:00 Part l – working with amplicon sequences l 09:00–10:45 09:00–10:45
    [Show full text]